SEARCH

SEARCH BY CITATION

References

  • 1
    Lohrum MA,Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol 2000; 10: 197202.
  • 2
    Courtois S,de Fromentel CC,Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 2004; 23: 6318.
  • 3
    Moll UM,Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 37186.
  • 4
    Moll UM,Erster S,Zaika A. p53, p63 and p73–solos, alliances and feuds among family members. Biochim Biophys Acta 2001; 1552: 4759.
  • 5
    Blandino G,Dobbelstein M. p73 and p63: why do we still need them? Cell Cycle 2004; 3: 88694.
  • 6
    Yang A,Walker N,Bronson R,Kaghad M,Oosterwegel M,Bonnin J,Vagner C,Bonnet H,Dikkes P,Sharpe A,McKeon F,Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99103.
  • 7
    Benard J,Douc-Rasy S,Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003; 21: 18291.
  • 8
    Casciano I,Mazzocco K,Boni L,Pagnan G,Banelli B,Allemanni G,Ponzoni M,Tonini GP,Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9: 24651.
  • 9
    Pozniak CD,Radinovic S,Yang A,McKeon F,Kaplan DR,Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000; 289: 3046.
  • 10
    Ikawa S,Nakagawara A,Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ 1999; 6: 115461.
  • 11
    Moll UM. The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Clin Cancer Res 2003; 9: 543741.
  • 12
    Flores ER,Sengupta S,Miller JB,Newman JJ,Bronson R,Crowley D,Yang A,McKeon F,Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 36373.
  • 13
    Frasca F,Vella V,Aloisi A,Mandarino A,Mazzon E,Vigneri R,Vigneri P. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003; 63: 582937.
  • 14
    Reynolds RM,Weir J,Stockton DL,Brewster DH,Sandeep TC,Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 2005; 62: 15662.
  • 15
    Kovacs GL,Gonda G,Vadasz G,Ludmany E,Uhrin K,Gorombey Z,Kovacs L,Hubina E,Bodo M,Goth MI,Szabolcs I. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005; 15: 1527.
  • 16
    Leenhardt L,Grosclaude P,Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004; 14: 105660.
  • 17
    Gomez Segovia I,Gallowitsch HJ,Kresnik E,Kumnig G,Igerc I,Matschnig S,Stronegger WJ,Lind P. Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984–2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population-based age-stratified analysis on thyroid carcinoma incidence. Thyroid 2004; 14: 27786.
  • 18
    Malaguarnera R,Mandarino A,Mazzon E,Vella V,Gangemi P,Vancheri C,Vigneri P,Aloisi A,Vigneri R,Frasca F. The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 2005; 12: 95371.
  • 19
    Ho YS,Tseng SC,Chin TY,Hsieh LL,Lin JD. p53 gene mutation in thyroid carcinoma. Cancer Lett 1996; 103: 5763.
  • 20
    Fagin JA,Matsuo K,Karmakar A,Chen DL,Tang SH,Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91: 17984.
  • 21
    Malaguarnera R,Vella V,Vigneri R,Frasca F. p53 family proteins in thyroid cancer. Endocr Relat Cancer 2007; 14: 4360.
  • 22
    Vella V,Zhu J,Frasca F,Li CY,Vigneri P,Vigneri R,Wang JY. Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem 2003; 278: 251517.
  • 23
    Motti ML,Califano D,Troncone G,De Marco C,Migliaccio I,Palmieri E,Pezzullo L,Palombini L,Fusco A,Viglietto G. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 2005; 166: 73749.
  • 24
    Sansal I,Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 295463.
  • 25
    Liaw D,Marsh DJ,Li J,Dahia PL,Wang SI,Zheng Z,Bose S,Call K,Tsou HC,Peacocke M,Eng C,Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 647.
  • 26
    Dahia PL,Marsh DJ,Zheng Z,Zedenius J,Komminoth P,Frisk T,Wallin G,Parson R,Longy M,Larsson C,Eng C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997; 57: 47103.
  • 27
    Yeager N,Klein-Szanto A,Kimura S,Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res 2007; 67: 95966.
  • 28
    Chen ML,Xu PZ,Peng XD,Chen WS,Guzman G,Yang X,Di Cristofano A,Pandolfi PP,Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 2006; 20: 156974.
  • 29
    Di Loreto C,Tell G,Pestrin M,Pandolfi M,Damante G,Puglisi F. PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 2005; 224: 1059.
  • 30
    Bruni P,Boccia A,Baldassarre G,Trapasso F,Santoro M,Chiappetta G,Fusco A,Viglietto G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000; 19: 314655.
  • 31
    Gimm O,Perren A,Weng LP,Marsh DJ,Yeh JJ,Ziebold U,Gil E,Hinze R,Delbridge L,Lees JA,Mutter GL,Robinson BG, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000; 156: 1693700.
  • 32
    Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007; 148: 94853.
  • 33
    Alvarez-Nunez F,Bussaglia E,Mauricio D,Ybarra J,Vilar M,Lerma E,de Leiva A,Matias-Guiu X. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 2006; 16: 1723.
  • 34
    Aiello A,Pandini G,Frasca F,Conte E,Murabito A,Sacco A,Genua M,Vigneri R,Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006; 147: 446375.
  • 35
    Sheng X,Koul D,Liu JL,Liu TJ,Yung WK. Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. Biochem Biophys Res Commun 2002; 292: 4226.
  • 36
    Stambolic V,MacPherson D,Sas D,Lin Y,Snow B,Jang Y,Benchimol S,Mak TW. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 31725.
  • 37
    Vikhanskaya F,Lee MK,Mazzoletti M,Broggini M,Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007; 35: 2093104.
  • 38
    Freeman DJ,Li AG,Wei G,Li HH,Kertesz N,Lesche R,Whale AD,Martinez-Diaz H,Rozengurt N,Cardiff RD,Liu X,Wu H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3: 11730.
  • 39
    Mayo LD,Dixon JE,Durden DL,Tonks NK,Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002; 277: 54849.
  • 40
    Zhou M,Gu L,Findley HW,Jiang R,Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003; 63: 635762.
  • 41
    Schweppe RE,Klopper JP,Korch C,Pugazhenthi U,Benezra M,Knauf JA,Fagin JA,Marlow LA,Copland JA,Smallridge RC,Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008; 93: 42267.
  • 42
    Baron V,Adamson ED,Calogero A,Ragona G,Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 2006; 13: 11524.
  • 43
    Wang Y,Blandino G,Oren M,Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 1998; 17: 192330.
  • 44
    Frasca F,Rustighi A,Malaguarnera R,Altamura S,Vigneri P,Del Sal G,Giancotti V,Pezzino V,Vigneri R,Manfioletti G. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 2006; 66: 29809.
  • 45
    Mayo LD,Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598603.
  • 46
    Ogawara Y,Kishishita S,Obata T,Isazawa Y,Suzuki T,Tanaka K,Musuyama N,Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 2184350.
  • 47
    Mandal M,Kim S,Younes MN,Jasser SA,El-Naggar AK,Mills GB,Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 2005; 92: 1899905.
  • 48
    Gomez-Rivera F,Santillan-Gomez AA,Younes MN,Kim S,Fooshee D,Zhao M,Jasser SA,Myers JN. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 2007; 13: 451927.
  • 49
    Yeager N,Brewer C,Cai KQ,Xu XX,Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res 2008; 68: 4449.
  • 50
    Domínguez G,García JM,Peña C,Silva J,García V,Martínez L,Maximiano C,Gómez ME,Rivera JA,García-Andrade C,Bonilla F. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24: 80515.
  • 51
    Concin N,Hofstetter G,Berger A,Gehmacher A,Reimer D,Watrowski R,Tong D,Schuster E,Hefler L,Heim K,Mueller-Holzner E,Marth C, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p 53–p 73 cross-talk in vivo. Clin Cancer Res 2005; 11: 837283.
  • 52
    Ishimoto O,Kawahara C,Enjo K,Obinata M,Nukiwa T,Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62: 63641.
  • 53
    Lokshin M,Li Y,Gaiddon C,Prives C. p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res 2007; 35: 34052.
  • 54
    Mondal N,Parvin JD. The tumor suppressor protein p53 functions similarly to p63 and p73 in activating transcription in vitro. Cancer Biol Ther 2005; 4: 4148.
  • 55
    Fontemaggi G,Kela I,Amariglio N,Rechavi G,Krishnamurthy J,Strano S,Sacchi A,Givol D,Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002; 277: 4335968.
  • 56
    Lee CW,La Thangue NB. Promoter specificity and stability control of the p53-related protein p73. Oncogene 1999; 18: 417181.
  • 57
    Virolle T,Adamson ED,Baron V,Birle D,Mercola D,Mustelin T,de Belle I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001; 3: 11248.
  • 58
    Kada F,Saji M,Ringel MD. Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metab Disord 2004; 4: 1815.
  • 59
    Nobuhara Y,Onoda N,Yamashita Y,Yamasaki M,Ogisawa K,Takashima T,Ishikawa T,Hirakawa K. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 2005; 92: 11106.
  • 60
    Mitsiades CS,Kotoula V,Poulaki V,Sozopoulos E,Negri J,Charalambous E,Fanourakis G,Tseleni-Balafouta S,Ain KB,Mitsiades N. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 2006; 91: 36626.
  • 61
    Younes MN,Kim S,Yigitbasi OG,Mandal M,Jasser SA,Dakak Yazici Y,Schiff BA,El-Naggar A,Bekele BN,Mills GB,Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 2005; 4: 114656.
  • 62
    Harms KL,Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ 2006; 13: 8907.
  • 63
    Toh WH,Logette E,Corcos L,Sabapathy K. TAp73beta and DNp73beta activate the expression of the pro-survival caspase-2S. Nucleic Acids Res 2008; 36: 4498509.
  • 64
    Yu J,Baron V,Mercola D,Mustelin T,Adamson ED. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ 2007; 14: 43646.